John J Chen1, Jacqueline A Leavitt2, Chengbo Fang3, Cynthia S Crowson4, Eric L Matteson4, Kenneth J Warrington5. 1. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. Electronic address: chen.john@mayo.edu. 2. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. 3. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota; Department of Ophthalmology, The First Affiliated Hospital of Anhui Medical University, Anhui, China. 4. Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota; Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 5. Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Abstract
PURPOSE: To determine the incidence of permanent visual loss from giant cell arteritis (GCA). DESIGN: Retrospective, population-based cohort. PARTICIPANTS: All residents of Olmsted County, Minnesota, diagnosed with GCA between January 1, 1950, and December 31, 2009. METHODS: All cases of GCA were identified using the Rochester Epidemiology Project (REP), which is a record-linkage system of medical records for all patient-physician encounters among Olmsted County, Minnesota, residents. The medical records were reviewed to identify and determine the cause of permanent vision loss among patients with GCA. Systemic symptoms of GCA and visual outcomes also were determined. MAIN OUTCOME MEASURES: Incidence and outcomes of permanent vision loss from GCA. RESULTS: Among the 245 new cases of GCA over the 60-year period, 20 patients (8.2%) had permanent vision loss due to GCA. The frequency of arteritic ischemic optic neuropathy (A-ION) was 6.9% (95% confidence interval [CI], 4.0-11.1) accounting for 85% of cases of permanent vision loss. The frequency of central retinal artery occlusion (CRAO) was 1.6% (95% CI, 0.4-4.2), and the frequency of cilioretinal artery occlusion was 0.4% (95% CI, 0.01-2.3). The population-based age- and sex-adjusted annual incidence of A-ION from GCA among persons aged ≥50 years was 1.3 (95% CI, 0.7-2.0) per 100 000 population. Some 20% of patients with permanent vision loss from GCA had vision loss without constitutional symptoms of GCA. Overall, there was no significant difference between presenting and final visual acuities. CONCLUSIONS: These population-based data provide the most accurate incidence of permanent vision loss from GCA. This study confirms that visual outcomes from GCA-related vision loss are poor and that 20% of patients with permanent visual loss from GCA can present without systemic symptoms of GCA.
PURPOSE: To determine the incidence of permanent visual loss from giant cell arteritis (GCA). DESIGN: Retrospective, population-based cohort. PARTICIPANTS: All residents of Olmsted County, Minnesota, diagnosed with GCA between January 1, 1950, and December 31, 2009. METHODS: All cases of GCA were identified using the Rochester Epidemiology Project (REP), which is a record-linkage system of medical records for all patient-physician encounters among Olmsted County, Minnesota, residents. The medical records were reviewed to identify and determine the cause of permanent vision loss among patients with GCA. Systemic symptoms of GCA and visual outcomes also were determined. MAIN OUTCOME MEASURES: Incidence and outcomes of permanent vision loss from GCA. RESULTS: Among the 245 new cases of GCA over the 60-year period, 20 patients (8.2%) had permanent vision loss due to GCA. The frequency of arteritic ischemic optic neuropathy (A-ION) was 6.9% (95% confidence interval [CI], 4.0-11.1) accounting for 85% of cases of permanent vision loss. The frequency of central retinal artery occlusion (CRAO) was 1.6% (95% CI, 0.4-4.2), and the frequency of cilioretinal artery occlusion was 0.4% (95% CI, 0.01-2.3). The population-based age- and sex-adjusted annual incidence of A-ION from GCA among persons aged ≥50 years was 1.3 (95% CI, 0.7-2.0) per 100 000 population. Some 20% of patients with permanent vision loss from GCA had vision loss without constitutional symptoms of GCA. Overall, there was no significant difference between presenting and final visual acuities. CONCLUSIONS: These population-based data provide the most accurate incidence of permanent vision loss from GCA. This study confirms that visual outcomes from GCA-related vision loss are poor and that 20% of patients with permanent visual loss from GCA can present without systemic symptoms of GCA.
Authors: Bhaskar Dasgupta; Frances A Borg; Nada Hassan; Leslie Alexander; Kevin Barraclough; Brian Bourke; Joan Fulcher; Jane Hollywood; Andrew Hutchings; Pat James; Valerie Kyle; Jennifer Nott; Michael Power; Ash Samanta Journal: Rheumatology (Oxford) Date: 2010-04-05 Impact factor: 7.580
Authors: Hans Petri; Alan Nevitt; Khaled Sarsour; Pavel Napalkov; Neil Collinson Journal: Arthritis Care Res (Hoboken) Date: 2015-03 Impact factor: 4.794
Authors: M C Cid; C Font; J Oristrell; A de la Sierra; B Coll-Vinent; A López-Soto; J Vilaseca; A Urbano-Márquez; J M Grau Journal: Arthritis Rheum Date: 1998-01
Authors: Abha G Singh; Tanaz A Kermani; Cynthia S Crowson; Cornelia M Weyand; Eric L Matteson; Kenneth J Warrington Journal: J Rheumatol Date: 2014-12-15 Impact factor: 4.666
Authors: Clara M Castillejo Becerra; Cynthia S Crowson; Matthew J Koster; Kenneth J Warrington; M Tariq Bhatti; John J Chen Journal: Neuroophthalmology Date: 2021-08-20
Authors: Jurij R Bilyk; Ann P Murchison; Benjamin T Leiby; Robert C Sergott; Ralph C Eagle; Laurence Needleman; Peter J Savino Journal: Trans Am Ophthalmol Soc Date: 2018-06-25
Authors: Edsel B Ing; Gabriela Lahaie Luna; Andrew Toren; Royce Ing; John J Chen; Nitika Arora; Nurhan Torun; Otana A Jakpor; J Alexander Fraser; Felix J Tyndel; Arun Ne Sundaram; Xinyang Liu; Cindy Ty Lam; Vivek Patel; Ezekiel Weis; David Jordan; Steven Gilberg; Christian Pagnoux; Martin Ten Hove Journal: Clin Ophthalmol Date: 2017-11-22